Wayne B Batchelor1, Abdulla A Damluji2, Celina Yong3, Mona Fiuzat4, Scott D Barnett2, David E Kandzari5, Matthew W Sherwood2, Kelly C Epps2, Behnam N Tehrani2, Dominic J Allocco6, Ian T Meredith6, JoAnn Lindenfeld7, Christopher M O'Connor8, Roxana Mehran9. 1. Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA. Electronic address: wayne.batchelor@inova.org. 2. Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA. 3. Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA. 4. Department of Medicine, Duke University School of Medicine, Durham, NC. 5. Piedmont Heart Institute, Atlanta, GA. 6. Boston Scientific Corp Marlborough MA. 7. Vanderbilt University Medical Center, Nashville, TN. 8. Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA; Department of Medicine, Duke University School of Medicine, Durham, NC. 9. Mount Sinai Medical Center, New York, NY.
Abstract
BACKGROUND: Minorities and women are underrepresented in cardiovascular research. Whether their higher enrollment can be predicted or influences research site performance is unclear. METHODS: We evaluated 104 sites that enrolled 4,184 patients in the U.S. Platinum Diversity (PD) and Promus Element Plus (PE Plus) studies (2012 to 2016). Research sites were ranked from lowest to highest minority and female enrollment, respectively. United States Census Bureau division and core-based statistical area (CBSA) populations were determined for each site and the following study performance metrics compared across quartiles of minority and female enrollment, respectively: (1) study subject enrollment rate (SER), (2) time to first patient enrolled, (3) rate of follow-up visits not done, (4) rate of follow-up visits out of window, and (5) protocol deviation rate (PDR). Multivariable regression was used to predict SER and PDR. RESULTS: Minority enrollment varied by region (P = .025) and population (P = .024) with highest recruitment noted in the Pacific, West South Central, South Atlantic, Mid-Atlantic and East North Central divisions. Female enrollment bore no relationship to region (P = .67) or population (P = .40). Median SER was similar in sites withi the highest vs lowest quartile of minority enrollment (SER of 4 vs 5 patients per month, respectively, P =0.78) and highest vs. lowest female enrollment (SER of 4 vs 4, respectively, P = .21). Median PDR was lower in sites within the highest vs lowest minority enrollment (0.23 vs 0.50 PDs per patient per month, respectively, P = .01) and highest vs. lowest female enrollment (0.28 vs. 0.37 PDs per patient per month, respectively, P = .04). However, this relationship did not persist after multivariable adjustment. All other site performance metrics were comparable across quartiles of minority and female enrollment. CONCLUSIONS: Minority, but not female enrollment, correlated with research site geographic region and surrounding population. High enrollment of minorities and women did not influence study performance metrics. These findings help inform future strategies aimed at increasing clinical trial diversity. TRIAL REGISTRATION: The PD and PE Plus studies are registered at www.clinicaltrials.gov under identifiers NCT02240810 and NCT01589978, respectively. KEY POINTS: Question: Does the enrollment of more Blacks, Hispanics and women in US cardiovascular research studies influence the overall rate of study subject enrollment and/or other key study site performance metrics and can diverse enrollment be predicted? FINDINGS: In this pooled analysis of 104 sites that enrolled 4,184 patients in the Platinum Diversity and Promus Element Plus Post-Approval Studies, we found that the enrollment of higher proportions of underrepresented minorities and women was univariately associated with lower protocol deviation rates while having no effect on other site performance metrics. A site's geographic location and surrounding population predicted minority, but not female enrollment. Meaning: These findings suggest that cardiovascular research subject diversity may be predicted from site characteristics and enhanced without compromising key study performance metrics. These insights help inform future strategies aimed at improving clinical trial diversity.
BACKGROUND: Minorities and women are underrepresented in cardiovascular research. Whether their higher enrollment can be predicted or influences research site performance is unclear. METHODS: We evaluated 104 sites that enrolled 4,184 patients in the U.S. Platinum Diversity (PD) and Promus Element Plus (PE Plus) studies (2012 to 2016). Research sites were ranked from lowest to highest minority and female enrollment, respectively. United States Census Bureau division and core-based statistical area (CBSA) populations were determined for each site and the following study performance metrics compared across quartiles of minority and female enrollment, respectively: (1) study subject enrollment rate (SER), (2) time to first patient enrolled, (3) rate of follow-up visits not done, (4) rate of follow-up visits out of window, and (5) protocol deviation rate (PDR). Multivariable regression was used to predict SER and PDR. RESULTS: Minority enrollment varied by region (P = .025) and population (P = .024) with highest recruitment noted in the Pacific, West South Central, South Atlantic, Mid-Atlantic and East North Central divisions. Female enrollment bore no relationship to region (P = .67) or population (P = .40). Median SER was similar in sites withi the highest vs lowest quartile of minority enrollment (SER of 4 vs 5 patients per month, respectively, P =0.78) and highest vs. lowest female enrollment (SER of 4 vs 4, respectively, P = .21). Median PDR was lower in sites within the highest vs lowest minority enrollment (0.23 vs 0.50 PDs per patient per month, respectively, P = .01) and highest vs. lowest female enrollment (0.28 vs. 0.37 PDs per patient per month, respectively, P = .04). However, this relationship did not persist after multivariable adjustment. All other site performance metrics were comparable across quartiles of minority and female enrollment. CONCLUSIONS: Minority, but not female enrollment, correlated with research site geographic region and surrounding population. High enrollment of minorities and women did not influence study performance metrics. These findings help inform future strategies aimed at increasing clinical trial diversity. TRIAL REGISTRATION: The PD and PE Plus studies are registered at www.clinicaltrials.gov under identifiers NCT02240810 and NCT01589978, respectively. KEY POINTS: Question: Does the enrollment of more Blacks, Hispanics and women in US cardiovascular research studies influence the overall rate of study subject enrollment and/or other key study site performance metrics and can diverse enrollment be predicted? FINDINGS: In this pooled analysis of 104 sites that enrolled 4,184 patients in the Platinum Diversity and Promus Element Plus Post-Approval Studies, we found that the enrollment of higher proportions of underrepresented minorities and women was univariately associated with lower protocol deviation rates while having no effect on other site performance metrics. A site's geographic location and surrounding population predicted minority, but not female enrollment. Meaning: These findings suggest that cardiovascular research subject diversity may be predicted from site characteristics and enhanced without compromising key study performance metrics. These insights help inform future strategies aimed at improving clinical trial diversity.
Authors: David E Kandzari; Nima Amjadi; Christopher Caputo; Steven K Rowe; Jerome Williams; Hoshedar P Tamboli; Thomas Christen; Dominic J Allocco; Keith D Dawkins Journal: Am J Cardiol Date: 2015-12-07 Impact factor: 2.778
Authors: Wayne B Batchelor; Stephen G Ellis; John A Ormiston; Gregg W Stone; Anita A Joshi; Hong Wang; Paul L Underwood Journal: J Interv Cardiol Date: 2012-09-18 Impact factor: 2.279
Authors: Jeffrey S Berger; Chiara Melloni; Tracy Y Wang; Rowena J Dolor; Camille G Frazier; Zainab Samad; Eric D Peterson; Daniel B Mark; L Kristin Newby Journal: Am Heart J Date: 2009-09-29 Impact factor: 4.749
Authors: Alice J Sheffet; George Howard; Albert Sam; Zafar Jamil; Fred Weaver; David Chiu; Jenifer H Voeks; Virginia J Howard; Susan E Hughes; Linda Flaxman; Mary E Longbottom; Thomas G Brott Journal: Stroke Date: 2017-11-30 Impact factor: 7.914
Authors: Ersilia M DeFilippis; Melvin Echols; Philip B Adamson; Wayne B Batchelor; Lauren B Cooper; Lawton S Cooper; Patrice Desvigne-Nickens; Richard T George; Nasrien E Ibrahim; Mariell Jessup; Dalane W Kitzman; Eric S Leifer; Martin Mendoza; Ileana L Piña; Mitchell Psotka; Fortunato Fred Senatore; Kenneth M Stein; John R Teerlink; Clyde W Yancy; JoAnn Lindenfeld; Mona Fiuzat; Christopher M O'Connor; Orly Vardeny; Muthiah Vaduganathan Journal: JAMA Cardiol Date: 2022-05-01 Impact factor: 30.154